Embecta (EMBC) Q1 2025 earnings summary

Executive summary

• Q1 FY2025 revenue was $261.9 million, down 5.6% year-over-year, mainly due to lower sales volume, prior period order timing, ERP-related inventory changes, and unfavorable FX, partially offset by higher contract manufacturing revenue and price increases.

• Strategic priorities include strengthening the core diabetes care business, expanding the product portfolio, and increasing financial flexibility through debt reduction and cost savings.

• Brand transition program is on track, with phased execution starting in H2 2025 in the U.S. and Canada.

• Restructuring plan, including discontinuation of the insulin patch pump program, is progressing and expected to complete by mid-2025.

• Progress made on GLP-1 initiatives to expand pen needle access and co-packaging with generic drugs.

Financial highlights

• Adjusted gross profit was $164.2 million (62.7% margin), down from $186.3 million (67.2%) year-over-year; GAAP gross profit was $157.1 million (60.0% margin).

• Adjusted operating income rose to $80.5 million (30.7% margin) from $77.5 million (27.9%); GAAP operating income was $28.7 million (11.0% margin), down from $45.5 million (16.4%).

• Adjusted net income was $38.3 million ($0.65 per share), up from $35.3 million ($0.61); GAAP net income was $0.0 million ($0.00 per share), down from $20.1 million ($0.35 per share).

• Adjusted EBITDA was $97.3 million (37.2% margin), up from $90.4 million (32.6%).

• Cash and equivalents at quarter-end were $216.7 million; $32.4 million in debt repaid during the quarter; total debt principal outstanding was $1.544–$1.569 billion.

Outlook and guidance

• FY2025 reported revenue guidance updated to $1,075–$1,092 million, reflecting a 4.3%–2.8% decline, mainly due to increased FX headwinds.

• Adjusted constant currency revenue growth expected at (2.5)% to (1.0)%.

• Adjusted gross margin guidance reaffirmed at 63.25%–64.25%; adjusted operating margin raised to 29.5%–30.5%; adjusted EBITDA margin raised to 36%–37%.

• Adjusted EPS guidance maintained at $2.70–$2.90, absorbing a $0.10 FX headwind.

• Targeting $110 million in debt reduction for FY25.